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Background: Epithelial-mesenchymal transition (EMT) has been proposed as a mechanism in the progression of
airway diseases and cancer. Here, we explored the role of acetylcholine (ACh) and the pathway involved in the
process of EMT, as well as the effects of mAChRs antagonist.
Methods: Human lung epithelial cells were stimulated with carbachol, an analogue of ACh, and epithelial and
mesenchymal marker proteins were evaluated using western blot and immunofluorescence analyses.
Results: Decreased E-cadherin expression and increased vimentin and α-SMA expression induced by TGF-β1 in
alveolar epithelial cell (A549) were significantly abrogated by the non-selective mAChR antagonist atropine and
enhanced by the acetylcholinesterase inhibitor physostigmine. An EMT event also occurred in response to
physostigmine alone. Furthermore, ChAT express and ACh release by A549 cells were enhanced by TGF-β1.
Interestingly, ACh analogue carbachol also induced EMT in A549 cells as well as in bronchial epithelial cells (16HBE)
in a time- and concentration-dependent manner, the induction of carbachol was abrogated by selective antagonist
of M1 (pirenzepine) and M3 (4-DAMP) mAChRs, but not by M2 (methoctramine) antagonist. Moreover, carbachol
induced TGF-β1 production from A549 cells concomitantly with the EMT process. Carbachol-induced EMT occurred
through phosphorylation of Smad2/3 and ERK, which was inhibited by pirenzepine and 4-DAMP.
Conclusions: Our findings for the first time indicated that mAChR activation, perhaps via M1 and M3 mAChR,
induced lung epithelial cells to undergo EMT and provided insights into novel therapeutic strategies for airway
diseases in which lung remodeling occurs.
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Signaling pathwayBackground
Epithelial-mesenchymal transition (EMT) is a process
whereby fully differentiated epithelial cells undergo tran-
sition to a mesenchymal phenotype, including changes in
the expression of epithelial markers, such as E-cadherin,
some cytokeratins, and mesenchymal markers, such
as vimentin, N-cadherin and α-smooth muscle actin
(α-SMA), as well as matrix metallopeptidase 9 (MMP-9)
[1,2]. EMT can, therefore, be regarded as a complex
manifestation of epithelial plasticity [3].* Correspondence: hongzhuan_chen@hotmail.com; yongyaocui@hotmail.com
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reproduction in any medium, provided the orEMT is increasingly recognized as one of the most im-
portant developmental biological processes in normal
wound healing. However, dysregulated EMT also appears
to occur in the progression and metastasis of cancer as
well as the pathogenesis of pulmonary diseases, such as
asthma, chronic obstructive pulmonary disease (COPD),
and pulmonary fibrosis [4-8]. Transforming growth fac-
tor (TGF)-β1 is thought to contribute to EMT and myo-
fibroblast differentiation [9-11]. A recently published
report demonstrated, however, that anticholinergic acli-
dinium inhibits human lung fibroblast to myofibroblast
transition induced by TGF-β1 stimulation [12]. Also
other reports have found that stimulation of muscarinic
acetylcholine receptors (mAChRs) augmented functional
TGF-β1 effects in human airway smooth muscle (ASM)d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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phosphorylation in lung fibroblasts was suppressed by
anticholinergic tiotropium [14]. These results suggested a
potential effect of the non-neuronal cholinergic system in
TGF-β1-mediated events. Although AChRs have pre-
viously been shown to be potential regulatory role in lung
fibroblast to myofibroblast transition, the role of acetyl-
choline (ACh) which serves as an autocrine or paracrine
growth factor in induction of EMT in lung epithelial cells
was relatively unexplored.
Airway epithelium presents all components of the cho-
linergic system, namely muscarinic receptors, ChAT, high-
affinity choline uptake, esterase, as well as ACh itself
[15,16]. Recently, it was demonstrated that ACh regulates
aspects of inflammation and remodeling through its ac-
tion on AChRs during airway diseases [17-19]. Incubation
of lung epithelial cells with ACh resulted in the release of
inflammatory mediators. The secretion of these mediators
was inhibited by tiotropium, a novel muscarinic antagonist
[20]. In epithelial cells derived from COPD patients and
smokers, ACh induced a significantly higher release of the
inflammatory mediator LTB4 compared to control cells.
This release of the lipid mediator was blocked by anti-
cholinergic treatment as well [21]. In a COPD model
of LPS-induced airway inflammation and remodeling in
guinea pigs, tiotropium abrogated the LPS-induced in-
crease in neutrophils, goblet cells, collagen deposition and
muscularised microvessels, but had no effect on em-
physema [22]. These results suggested that endogenous
acetylcholine plays a major role in the pathogenesis of this
disease. EMT takes center stage as the convergence point
between inflammation and airway diseases. Inflammatory
mediators are known to induce downregulation of epithe-
lial cell–cell adhesion and promote mesenchymal gene ex-
pression both in vitro and in vivo, and consequently
inflammatory mediators have emerged as decisive factors
in EMT induction. Although a number of molecules in-
volved in ACh-mediated airway inflammation and remo-
deling have been identified, little is known regarding the
role of ACh in EMT.
In the current study, we explored (1) whether TGF-β1-
induced EMT can be influenced by non-neuronal choli-
nergic system in lung epithelial cells, and if so, (2) whether
mAChR activation has similar effects to TGF-β1 in EMT
induction. Moreover, (3) which of the two main pathways,
the Smad pathway or the ERK pathway, both of which can
be activated by mAChR agonists, was involved in EMT in
lung epithelial cells.
Methods
Cell culture and treatment
The human alveolar epithelial cell line A549 and human
tracheobronchial epithelial cell line 16HBE were obtained
from the American Type Culture Collection (Manassas,VA, USA), and were maintained in Ham’s F-12 medium
(Gibco, Grand Island, NY, USA) or Dulbecco’s modi-
fied Eagle’s medium (DMEM)/HIGH Glucose (HyClone,
Logan, UT, USA) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (Gibco) in a
humidified incubator with 5% CO2 at 37°C.
Cells were grown in 96- or 6-well plastic tissue culture
plates until confluence and then transferred into serum-
free medium containing 0.1% FBS for 24 h. After that,
cells were treated as designed.
Western blot analysis
Cells were lysed in RIPA lysis buffer (50 mM Tris, pH7.4,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS) and a protease inhibitor cocktail (1 mM phenyl-
methylsulfonyl fluoride, 10 μg/ml pepstatin A, 10 μg/ml
aprotinin and 5 μg/ml leupeptin) on ice for 5 min and
scraped into a centrifuge tube. The lysates were centri-
fuged at 13,000 × g for 5 min at 4°C. Total protein was
mixed with sodium dodecyl sulfate (SDS) sample buffer
and heated at 100°C for 5 min. Equal amounts of samples
were separated by 10% SDS-polyacrylamide gel electro-
phoresis and transferred to polyvinylidene fluoride mem-
branes, which were then blocked with 5% non-fat milk in
TBS-T (Tris-HCl 50 mM, NaCl 150 mM, Tween-20 0.1%)
for 1 h at room temperature (RT) and then incubated with
primary antibodies overnight at 4°C. After washing the
membranes three times for 5 min each with TBS-T, they
were incubated with horseradish peroxidase-conjugated
secondary antibodies for 1 h at RT, followed by an
additional three washes for 5 min each with TBS-T. Bands
were subsequently visualized on film using enhanced
chemiluminescence reagents. Results were expressed
relative to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) band density used as a loading control. The
following antibodies were used: E-cadherin, vimentin,
MMP-9 (Cell Signaling Technology, MA, USA), α-SMA
(Abcam, MA, USA), GAPDH (Santa Cruz Biotechnology,
CA, USA), and ChAT (Millipore Bioscience Research
Reagents, CA, USA).
Determination of ACh by LC–MS/MS
ACh levels in the supernatants of A549 cells were deter-
mined by LC–MS/MS as previously described [23].
Immunofluorescence
Cells were grown on chamber slides and treated as
designed. After intermediate washes with cold phosphate-
buffered saline (PBS), the cells were fixed with 4.0% para-
formaldehyde in PBS for 15 min at RT. The cells were
rinsed in cold PBS and blocked in 5% bovine serum
albumin for 1 h at RT. The cells were then incubated with
primary antibodies overnight at 4°C, washed with cold
PBS, incubated with Alexa Fluor-conjugated secondary
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stained with 1 μg/mL (w/v) 4,6-diamidino-2-phenylindole
(DAPI) for 5 min at RT. After washing, images were col-
lected using an Axioscope microscope system (Carl Zeiss
AG, Jena, Germany) at 40× magnification. The following
antibodies were used: E-cadherin (dilution, 1:200), α-SMA
(1:200), and vimentin (1:800).
Measurement of TGF-β1
The amount of TGF-β1 in the supernatants of A549
cells was determined using enzyme-linked immunosor-
bent assay kits (Rapidbio Lab, West Hills, CA, USA) ac-
cording to the manufacturer’s instructions.
Statistics analysis
All data are expressed as mean ± SEM. Data were
analyzed by one-way ANOVA (Dunnett’s test) or the
Mann-Whitney test where appropriate and statistical
significance was accepted at a p-value of < 0.05. Statis-
tical analyses were performed using Prism version 5.0
(Graph-Pad Software, USA).
Results
TGF-β1-induced EMT is attenuated by mAChR antagonist
EMT is defined by changes in gene expression in which
epithelial markers are decreased while mesenchymal
markers are increased. We examined whether TGF-β1-
induced EMT events could be modulated by mAChRs in
lung epithelial cells. As expected, A549 cells exposed to
TGF-β1 for 72 h resulted in a decrease in the epithelial
marker E-cadherin (p < 0.01), as well as an increase in the
mesenchymal markers vimentin (p < 0.01) and α-SMAFigure 1 Effect of mAChR antagonists on TGF-β1-induced EMT in A54
stimulation with TGF-β1 (5 ng/mL) for 72 h. Cell lysates were assayed for E
(A), vimentin (B), α-SMA (C) and GAPDH are shown. Data are expressed as
analysis. ##p < 0.01 vs. control; **p < 0.01 vs. TGF-β1.(p < 0.01) (Figure 1A, B, C). Interestingly, TGF-β1-induced
EMT events were significantly arrested by the non-
selective mAChR antagonist atropine in a dose-dependent
manner (0.1–10 μM) (Figure 1A, B, C). This result sug-
gested a modulatory effect of mAChRs and prompted us
to surmise a potential effect of endogenous ACh in EMT
induction.
TGF-β1- induced EMT is modulated by non-neuronal
cholinergic system
To further assess the potential effect of endogenous ACh
in EMT events in A549, the acetylcholinesterase (AChE)
inhibitor physostigmine was used to increase the amount
of ACh by blocking ACh degradation. Interestingly, how-
ever, a significant, additive effect was observed by the
combined administration of physostigmine and TGF-β1
at 72 h post-stimulation. The change in the expression
of TGF-β1-induced E-cadherin, vimentin, and α-SMA
was significantly enhanced (p < 0.01) by physostigmine
(100 μM) compared with TGF-β1 alone (Figure 2A, B, C).
In addition, the EMT event also occurred in the presence
of physostigmine alone compared with controls (p < 0.01)
(Figure 2A, B, C).
Having observed the effect of AChE inhibitor on EMT
process, we went on to measure ACh levels in the su-
pernatants of cultured A549 cells. This was evaluated by
western blot analysis. The ChAT is key enzyme for ACh
synthesis and, therefore, the expression of ChAT super-
natant levels definitively demonstrated to prove the ex-
istence of the endogenous ACh. As shown in Figure 2D,
high level expression of ChAT was observed in A549
cells stimulated by TGF-β1, and TGF-β1-induced ChAT9 cells. Cells were treated with atropine (0.1–10 μM) 1 h before
MT markers and GAPDH. Representative western blots of E-cadherin
mean ± SEM of 3–5 independent experiments after densitometric
Figure 2 TGF-β1-induced EMT is modulated by non-neuronal cholinergic system. Physostigmine (Physo, 100 μM) was added 1 h before
stimulation with TGF-β1 (5 ng/mL) for 72 h. ACh in supernatants was determined with an LC–MS/MS assay. Cell lysates were assayed for EMT
markers, ChAT and GAPDH. Representative western blots of E-cadherin (A), vimentin (B), α-SMA (C), ChAT (D) and GAPDH are shown. E: ACh
level. Data are expressed as mean ± SEM of 4-6 independent experiments. #p < 0.05, ##p < 0.01 vs. control; *p < 0.05, **p < 0.01 vs. TGF-β1.
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determine if A549 cells express the ChAT needed for
ACh synthesis and release, LC-MS/MS were performed.
As shown in Figure 2E, in non-stimulated cells, the ACh
levels in the culture supernatants were close to the
assay’s limit of detection (1.93 ± 0.09 ng/ml). The ad-
dition of physostigmine to non-stimulated A549 cell cul-
tures was not associated with a significant increase in
ACh levels (1.90 ± 0.15 ng/ml), which were close to the
limit of detection. However, the ACh could be readily
detected in the presence of TGF-β1 with a significant in-
crease in ACh levels (2.39 ± 0.16 ng/ml). Physostigmineenhanced TGF-β1-induced ACh release by 28%, when
compared with TGF-β1 alone (TGF-β1 + physostigmine:
3.07 ± 0.07 ng/ml). Thus, these findings demonstrate
that ChAT express and ACh release by A549 cells were
enhanced by TGF-β1, and the levels of ACh are modu-
lated by AChE.
Carbachol induces EMT-related changes in lung epithelial
cells
If endogenous ACh is involved in TGF-β1-induced
EMT, the application of an exogenous mAChR agonist
should have the same effect as endogenous ACh. As
Figure 3 (See legend on next page.)
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Figure 3 Carbachol induces EMT-related changes in A549 cells. Cells were stimulated with TGF-β1 (5 ng/mL) or carbachol (0.1–10 μM) for 72 h
(A), carbachol (1 μM) for the indicated times (B), or with the addition of pirenzepine (10 μM), methoctramine (10 μM), or 4-DAMP (1 μM) administered
1 h before carbachol (1 μM) for 72 h (C). Cell lysates were assayed for EMT markers and GAPDH. Representative western blots of E-cadherin, vimentin,
α-SMA and GAPDH are shown. (D) Cells were treated with 4-DAMP (1 μM) 1 h before stimulation with carbachol (1 μM) for 72 h. Cells were fixed and
stained with E-cadherin, vimentin and α-SMA antibodies, and then incubated with Alexa Fluor-conjugated secondary antibodies and DAPI for nuclei
labeling. E-cadherin (green), vimentin (purple), α-SMA (red) and nuclei (blue) were visualized using confocal fluorescence microscopy. Data are expressed
as mean ± SEM of 3–5 independent experiments after densitometric analysis. #p < 0.05, ##p < 0.01 vs. control; *p < 0.05, **p < 0.01 vs. carbachol.
Yang et al. BMC Pulmonary Medicine 2014, 14:53 Page 6 of 11
http://www.biomedcentral.com/1471-2466/14/53shown in Figure 3A, B, C, carbachol dramatically de-
creased E-cadherin expression, and increased expression
of vimentin and α-SMA in A549 cells in a concen-
tration-dependent manner (Figure 3A). The expression
levels of E-cadherin, vimentin and α-SMA significantly
changed at 48 h and peaked at 72 h (Figure 3B). It is in-
teresting to note that carbachol at concentrations as low
as 0.1 μM was sufficient to induce EMT phenotypic
markers with a maximal response at 10 μM. Furthermore,
carbachol-induced EMT can be abrogated by pirenzepine
(M1 mAChR antagonist, 10 μM) and diphenyl-acetoxy-4-
methylpiperidine methiodide (4-DAMP, an M3 mAChR
antagonist, 1 μM), but not methoctramine (an M2 mAChR
antagonist, 10 μM) (Figure 3C).
To further confirm changes in E-cadherin, vimentin,
and α-SMA, immunofluorescence analysis was performed
to assess the roles of carbachol on these markers in A549
cells. Confocal laser scanning microscopy images in un-
treated control cells revealed localized expression of the
epithelial marker E-cadherin at cell borders and relatively
low expression of the mesenchymal markers vimentin and
α-SMA (Figure 3D). Stimulation with 1 μM carbachol
for 72 h reduced membrane-associated expression of
E-cadherin with loss of expression at cell borders and con-
comitant dramatic increases in expression of vimentin
and α-SMA in contrast to untreated control cells, and
these effects were reversed by the mAChR antagonist
4-DAMP (Figure 3D).
To ensure that these findings were not unique to A549
cells, we performed parallel experiments using the human
bronchial epithelial cell line 16HBE to assess whether
bronchial epithelial cells also undergo EMT during car-
bachol stimulation. Western blot analysis revealed that
E-cadherin expression was decreased in the same manner
as in A549 cells, whereas MMP-9 and α-SMA expression
in 16HBE cells was increased by carbachol treatment
(Figure 4A). The effect of carbachol was significantly
inhibited by pirenzepine (10 μM) and 4-DAMP (1 μM),
but not methoctramine (10 μM) (Figure 4B).
Carbachol-induced EMT related to TGF-β1 release from
A549 cells
We next investigated whether carbachol-induced EMT
was related to TGF-β1 expression. To this aim, westimulated A549 cells for 24 h with carbachol and analyzed
EMT events. We found that carbachol induced TGF-β1
production in the supernatant of A549 cells in a time- (6–
24 h) and concentration- (0.1–10 μM) dependent manner
(Figure 5A and B). Moreover, carbachol-induced TGF-β1
expression was completely abrogated by atropine (10 μM),
pirenzepine (10 μM), and 4-DAMP (1 μM) (Figure 5C).
These findings suggested that carbachol-induced EMT
may be, in part, due to TGF-β1, and cooperative regulation
in EMT by mAChR activation and TGF-β1 expression.
Involvement of the Smad and ERK pathways in
carbachol-induced EMT
To confirm whether the Smad and ERK pathways, both of
which can be activated by mAChR agonists, were involved
in carbachol-induced EMT in A549 cells, pharmacological
inhibitors were used to inhibit each pathway. We found
that carbachol-induced EMT was completely inhibited by
addition of the TGF-β/Smad inhibitor SB431542 (10 μM)
and the ERK inhibitor U0126 (5 μM) (Figure 6A). More-
over, both Smad2/3 and ERK phosphorylation induced by
1 μM carbachol were significantly inhibited by 10 μM pir-
enzepine and 1 μM 4-DAMP (Figure 6B). These fin-
dings indicated that both the Smad2/3 and ERK signaling
pathways were involved in carbachol-induced EMT and
mAChR activation, perhaps M1 and M3 mAChRs induce
downstream target gene expression during the EMT
process.
Discussion
Our work revealed that TGF-β1-induced EMT in lung
epithepial cells can be abrogated by mAChR antagonist
and enhanced by the AChE inhibitor, and that ACh
synthesis and release from lung epithelial cells can be
enhanced by TGF-β1. In addition, mAChR stimulation
with ACh analogue carbachol also induced lung epithelial
cells to undergo EMT. Our findings demonstrated that
non-neuronal cholinergic system components involved in
EMT in lung epithelial cells and provided insights into
novel therapeutic strategies for airway diseases in which
lung remodeling occurs.
Several studies have reported increased TGF-β expression
in the airway epithelium of patients with obstructive airway
diseases [9,24]. Furthermore, there is much evidence that
Figure 4 Carbachol induces EMT-related changes in 16HBE cells. Cells were stimulated with TGF-β1 (5 ng/mL) or carbachol (0.1–10 μM) for
72 h (A) or with the addition of pirenzepine (10 μM), methoctramine (10 μM), or 4-DAMP (1 μM), which was administered 1 h before carbachol
(1 μM) for 72 h (B). Cell lysates were assayed for EMT markers and GAPDH. Representative western blots of E-cadherin, MMP-9, α-SMA, and
GAPDH are shown. Data are expressed as mean ± SEM of six independent experiments after densitometric analysis. #p < 0.05, ##p < 0.01 vs. control;
*p < 0.05, **p < 0.01 vs. carbachol.
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monary alveolar surface is lined with type I and type II
epithelial cells. Type II cells are since long recognized as
important players of the innate immune system, produ-
cing cytokines and chemokines. The cancer-derived hu-
man alveolar epithelial cell line A549 is widely
acknowledged as a relevant model of type II alveolar epi-
thelial cells and the ability to undergo EMT in vitro has
been confirmed [10]. We also observed an almost identical
EMT pattern following stimulation with carbachol in
16HBE cells. As a result, carbachol-induced EMT events
were not limited to alveolar epithelial cells, but also
extended to bronchial epithelial cells in vitro, although
there were differences in the expression of the typicalmesenchymal markers vimentin and MMP-9 between
A549 and 16HBE cells. This difference in expression pro-
files might have been due to variances between the cells
types investigated. The present findings were in accor-
dance with other studies in which TGF-β1 reduced E-
cadherin mRNA levels while simultaneously increasing
expression of α-SMA and MMP-9, but not vimentin, in
human bronchial epithelial cells (BEAS-2B) [27], and
TGF-β1 had almost no effect on MMP-9 expression in
the A549 cell line [10].
Epithelial cells can express the machinery of the non-
neuronal cholinergic system, comprising ACh-synthesizing
choline acetyltransferase, the vesicular ACh transporter, nic-
otinic ACh receptors, mAChRs, and the ACh-hydrolyzing
Figure 5 Effect of carbachol on TGF-β1 release by A549 cells.
Cells were stimulated with carbachol (10 μM) for the indicated times
(A) or carbachol (0.1–10 μM) for 24 h (B), or with the addition of
atropine (10 μM), pirenzepine (10 μM), methoctramine (10 μM), or
4-DAMP (1 μM), which was administered 1 h before stimulation with
carbachol (1 μM) for 24 h (C). Data are expressed as mean ± SEM. from
at least four experiments. #p < 0.05, ##p < 0.01 vs. control; *p < 0.05,
**p < 0.01 vs. carbachol.
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[28-30]. The cells were able to synthesize and release ACh
[20,23,31] and could also be activated by ACh itself. Of the
five molecular subtypes of mAChR, three (M1 mAChR, M2
mAChR, and M3 mAChR) reportedly mediate distinct
physiological functions in the lung.
In our present study, we found that TGF-β1-induced
EMT could be modulated by mAChR antagonists and
that A549 cells stimulated with TGF-β1 synthesize and
secrete ACh, suggesting a potential effect of endogenous
ACh in EMT induction. Further studies supported the
idea that the ACh analog carbachol induced EMT re-
sulting in dramatic down-regulation of E-cadherin, and
up-regulation of vimentin and α-SMA in lung epithelial
cells. Similar findings were described in the transition of
human lung fibroblasts to myofibroblasts [12]. Interes-
tingly, low doses of carbachol (0.1 μM) induced loss of
epithelial marker expression in A549 cells and concur-
rent gains in mesenchymal markers. The data obtained
in the present study extend and reinforce our previous
speculations and showed that the cellular switch from
an epithelial to mesenchymal-like phenotype may be oc-
curred in lung epithelial cells and triggered by endogen-
ous ACh secreted by A549 cells. Also, in accordance
with our previous findings, the effect of physostigmine
alone and in combination with TGF-β1, this was able to
upregulate choline acetyltransferase expression in A549
cells. Therefore, we reasoned that the physostigmine-
related EMT event observed in the present study increased
the amount of ACh by blocking ACh degradation and acti-
vating mAChRs in A549 cells. Importantly, epithelial cells
(e.g., A549 cells) express all of the necessary components
to synthesize and release ACh by themselves, which acts
as an autocrine growth factor via mAChR activation [32].
Recent studies have revealed that in addition to inflam-
mation, ACh regulates important aspects of lung structure
via the M1 or M3 mAChR pathways. Indeed, M1 or M3
mAChRs are both expressed by structural cells of the air-
ways, including epithelial cells and ASM cells [23,33].
Moreover, in vitro studies have demonstrated a role for
M1 or M3 mAChR in the regulation of ASM proliferation
[34]. In our study, we found that carbachol-induced EMT
can be abrogated by M1 or M3 mAChR-selective antago-
nists. In fact, the involvement of mAChRs in carbachol-
induced EMT supported the finding that the EMT process
Figure 6 The involvement of the Smad and ERK pathways in carbachol-induced EMT in A549 cells. The TGF-β/Smad inhibitor (SB431542,
10 μM), the ERK inhibitor (U0126, 5 μM), pirenzepine (10 μM), or 4-DAMP (1 μM) was administered 1 h before stimulation with carbachol (1 μM).
Cell lysates were assayed for EMT markers and GAPDH after incubation for 72 h (A). The expression of Smad2/3/p-Smad2/3 and ERK/p-ERK were
detected after incubation for 1 h and 72 h, respectively. (B). Representative western blots are shown. Data are expressed as mean ± SEM of 4–6
independent experiments after densitometric analysis. #p < 0.05, ##p < 0.01 vs. control; *p < 0.05, **p < 0.01 vs. carbachol.
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acting on lung epithelial cells. This finding was in accor-
dance with the results reported by Milara et al., which
showed that M1 and M3 mAChRs were involved in
carbachol- or TGF-β1-induced fibroblast to myofibroblast
transition in human lung fibroblasts [12].
Since both carbachol and TGF-β1 can induce EMT via
epithelial to mesenchymal transition, an interaction bet-
ween mAChRs and TGF-β1 in EMT induction may also
be expected. Kong et al. found a cooperative regulation by
G protein-coupled receptor ligands and growth factors
[35]. Recently, a strong relationship between mAChRs andTGF-β1 has been illustrated, and carbachol stimulation
has been reported to increase TGF-β1 expression [12].
However, emerging evidence suggests that an interaction
of mAChR activation and TGF-β1 expression may con-
tribute to EMT induction. The results of the present study
suggested that (1) TGF-β1-induced EMT can be inhibited
by mAChR antagonists, (2) mAChR activation induced
TGF-β1 expression in A549 cells, and (3) TGF-β1-induced
EMT was enhanced by AChE inhibitor which increased
the amount of ACh, and lung epithelial cells synthesize
and secrete ACh in response to TGF-β1. Thus, the inter-
action between mAChRs and TGF-β1 in EMT induction
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the signaling pathways governing TGF-β1-mediated EMT
events as a result of enhanced EMT processes. This fin-
ding was unexpected and suggested that cooperative regu-
lation by mAChR activation and TGF-β1 was involved in
EMT, leading to airway remodeling.
Accumulating evidence has indicated that, in addition
to Smad2-mediated pathways [3,10,36], other pathways,
such as the p38, ERK, c-Jun N-terminal kinase, and
mitogen-activated protein kinase pathways have been im-
plicated in TGF-β signaling [14,37]. In the present study,
we provide new evidence on the mechanism by which
carbachol increases the release of the TGF-β1, the
phosphorylation of Smad2/3 and ERK, thus promoting
the EMT process in lung epithelial cells. These findings
extend and reinforce other report from human bronchial
fibroblasts that TGF-β1 activated non-neuronal choliner-
gic system [12]. Furthermore, we observed that mAChRs
antagonist (M1 and M3) suppressed the release of TGF-
β1 and the phosphorylation of Smad2/3 and ERK which
activated by carbachol resulting in suppression of EMT
process. Collectively, these findings suggested that the
Smad2/3 and ERK signaling pathways involved in EMT
were trigged by mAChR agonists and that a crosstalk of
the ERK and TGF-β signaling pathways may potentiate
and synergize the canonical TGF-β-Smad pathway, al-
though further work is obviously needed to rule out the
effects of other signaling pathways.
Conclusion
In summary, our results point towards a crosstalk between
mAChR activation and TGF-β1 expression in EMT induc-
tion in lung epithelial cells and demonstrated that lung
epithelial cells secreting ACh may function as an autocrine
growth factor via activation of M1 and M3 mAChRs to in-
duce EMT through the Smad2/3 and ERK signaling path-
ways. These findings demonstrated for the first time the
role of non-neuronal cholinergic system in EMT and pro-
vided insights into novel therapeutic strategies for airway
diseases in which lung remodeling occurs.
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